Developer docs
API playgroundTry for free, no card

Search company profiles

Trilogy Writing & Consulting

Full company profile

uuid000etz9

Namestring
Trilogy Writing & Consulting
Legal namestring
Trilogy Writing & Consulting GmbH
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Trilogy Writing & Consulting GmbH is a Frankfurt, Germany-based professional services firm founded in 2002 that provides specialized regulatory and clinical documentation services to life sciences and pharmaceutical companies. Its work centers on producing the documentation required across the clinical development lifecycle — including clinical study reports, regulatory dossiers, and submissions to agencies such as the FDA and EMA — for therapies including biologics and specialty drugs. The firm addresses documented customer pain points around regulatory complexity, rising clinical trial volume, and the need for compliant technical writing under stringent frameworks.

Trilogy operates as a B2B professional services provider rather than a software platform; value is delivered through human regulatory writing expertise, and the underlying "technology" in the disclosed data is not characterized beyond standard professional services tooling. The company serves a single primary vertical (pharmaceutical and life sciences sponsors) and, based on available commentary, reaches customers via direct and enterprise sales channels. Pricing models, contract structures, revenue mechanics, and named customers are not publicly disclosed, and no app, API, or productized technology offering is described in the source material.

In March 2024, Trilogy was acquired by Indegene Limited, a strategic operating company in the broader pharma services space. The acquisition folded Trilogy into Indegene's medical writing and regulatory services portfolio, giving it access to a larger ecosystem of digital, medical, and commercial capabilities and a wider geographic footprint than Trilogy likely operated as an independent firm. Operating geographies, named customers, leadership team, and financial performance are not disclosed in the available sources, limiting visibility into post-acquisition scale and trajectory.

Short descriptiontext

Trilogy Writing & Consulting is a Frankfurt-based regulatory writing consultancy serving pharmaceutical and life sciences companies with clinical and regulatory documentation. Founded in 2002, the firm has been a subsidiary of Indegene Limited since March 2024.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersFrankfurt, Germany
HQ citystring
Frankfurt
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
regulatory medical writing, clinical trial documentation, pharmaceutical regulatory services, life sciences consulting, regulatory affairs support
Industry3 codes
PRIMARYHLAGALAG
Medical Writing & Publications (Clinical/Safety/HEOR)
SECONDARYHLAGAOAC
Medical Writing & Clinical Documentation FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLAGAKAC
Regulatory Operations & Publishing (eCTD, RIM, Submission Management)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code2 codes
  • Other Scientific and Technical Consulting Services54169
  • Management Consulting Services54161
SIC code1 code
  • Services-Management Consulting Services8742
Product category
Regulatory Medical Writing Services
Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Trilogy Writing & Consulting provides specialized regulatory and clinical documentation services for the life sciences sector. The firm supports pharmaceutical and biotechnology companies in producing documentation required for clinical development, regulatory submissions, and compliance with stringent regulatory frameworks. It operates as a regulatory medical writing consultancy with deep domain expertise in clinical and submission documentation.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1Regulatory Medical Writing Services
CategoryRegulatory Writing / Medical Communications
2Clinical Trial Documentation Support
CategoryClinical Development Services
3Regulatory Compliance Documentation for Biologics and Specialty Drugs
CategoryRegulatory Affairs Consulting
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Labcorp Drug Development, formerly Covance, provides clinical development and regulatory services including medical writing to pharma sponsors. Its integrated CRO model with embedded writing functions makes it a broadly comparable incumbent peer to Trilogy's specialized offering.

TypeDirect peer
Description

Parexel is a top-tier CRO with dedicated regulatory writing and medical communications services serving global pharma and biotech sponsors. It competes directly with Trilogy for the same regulatory documentation work and across similar clinical submission use cases, and is one of the most direct comparables in the medical writing FSP space.

TypeDirect peer
Description

Freyr is a global regulatory services and medical writing specialist serving pharma, biotech, and medical device companies. Its dedicated focus on regulatory documentation, submissions, and compliance aligns closely with Trilogy's core offering and customer base.

TypeBroad incumbent
Description

ICON is a leading global CRO with significant regulatory writing, biostatistics, and clinical services capabilities. It is a direct competitor for outsourced regulatory writing contracts with pharma and biotech sponsors and offers comparable FSP-style engagements at global scale.

TypeEmerging player
Description

ProPharma Group provides regulatory affairs, compliance, and medical writing consulting services to pharma and biotech. Its overlap with Trilogy is more concentrated in regulatory and quality-focused projects, positioning it as a focused emerging player in adjacent regulatory services.

TypeBroad incumbent
Description

Indegene is Trilogy's parent company and a global healthcare commercialization and clinical services firm. While Indegene operates across the broader pharma services value chain, its regulatory writing portfolio — of which Trilogy is the centerpiece — directly overlaps with Trilogy's specialty. It is the most relevant comparison for benchmarking Trilogy's service scope and scale within a strategic acquirer's platform.

TypeBroad incumbent
Description

IQVIA is a global CRO and life sciences services giant offering regulatory and medical writing within its broader clinical development portfolio. While its remit extends across the full clinical and commercial stack, its medical writing practice competes for the same embedded writing engagements Trilogy targets, making it a relevant broad incumbent peer.

TypeRegional player
Description

TFS HealthScience (acquired by Ergomed) is a European-headquartered CRO with a strong medical writing and clinical services practice serving global sponsors. Its Nordic and European base, combined with writing-focused FSP services, makes it a directly comparable European regional peer to Trilogy's Frankfurt-rooted operation.

TypeBroad incumbent
Description

Syneos Health is a clinical and commercial services organization offering regulatory and medical writing within its broader biopharmaceutical solutions portfolio. It serves similar sponsor customers and competes for similar writing engagements.

TypeDirect peer
Description

Cactus Communications, through its Cactus Life Sciences division, provides medical writing, publication support, and regulatory documentation services to global pharma and biotech sponsors. It is one of the closest direct peers to Trilogy in terms of pure-play medical writing and FSP offerings for clinical and regulatory documents.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Trilogy Writing & Consulting

Regulatory Medical Writing Servicestrilogywriting.com

Trilogy Writing & Consulting is a Frankfurt-based regulatory writing consultancy serving pharmaceutical and life sciences companies with clinical and regulatory documentation. Founded in 2002, the firm has been a subsidiary of Indegene Limited since March 2024.

What Trilogy Writing & Consulting does

Trilogy Writing & Consulting GmbH is a Frankfurt, Germany-based professional services firm founded in 2002 that provides specialized regulatory and clinical documentation services to life sciences and pharmaceutical companies. Its work centers on producing the documentation required across the clinical development lifecycle — including clinical study reports, regulatory dossiers, and submissions to agencies such as the FDA and EMA — for therapies including biologics and specialty drugs. The firm addresses documented customer pain points around regulatory complexity, rising clinical trial volume, and the need for compliant technical writing under stringent frameworks.

Trilogy operates as a B2B professional services provider rather than a software platform; value is delivered through human regulatory writing expertise, and the underlying "technology" in the disclosed data is not characterized beyond standard professional services tooling. The company serves a single primary vertical (pharmaceutical and life sciences sponsors) and, based on available commentary, reaches customers via direct and enterprise sales channels. Pricing models, contract structures, revenue mechanics, and named customers are not publicly disclosed, and no app, API, or productized technology offering is described in the source material.

In March 2024, Trilogy was acquired by Indegene Limited, a strategic operating company in the broader pharma services space. The acquisition folded Trilogy into Indegene's medical writing and regulatory services portfolio, giving it access to a larger ecosystem of digital, medical, and commercial capabilities and a wider geographic footprint than Trilogy likely operated as an independent firm. Operating geographies, named customers, leadership team, and financial performance are not disclosed in the available sources, limiting visibility into post-acquisition scale and trajectory.

Trilogy Writing & Consulting firmographics

Firmographics
Name
Trilogy Writing & Consulting
Legal name
Trilogy Writing & Consulting GmbH
Website
https://trilogywriting.com
Company type
Private
Founded year
2002
Operating status
Acquired
Headcount range
101–250 employees
Short description
Trilogy Writing & Consulting is a Frankfurt-based regulatory writing consultancy serving pharmaceutical and life sciences companies with clinical and regulatory documentation. Founded in 2002, the firm has been a subsidiary of Indegene Limited since March 2024.
Ownership category
akta.pro rank

Trilogy Writing & Consulting industry classification

Industry
Product category
Regulatory Medical Writing Services
NAICS
Other Scientific and Technical Consulting Services (54169), Management Consulting Services (54161)
SIC
Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYHLAGALAG
Medical Writing & Publications (Clinical/Safety/HEOR)
SECONDARYHLAGAOAC
Medical Writing & Clinical Documentation FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLAGAKAC
Regulatory Operations & Publishing (eCTD, RIM, Submission Management)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Regulatory medical writing
  • Clinical trial documentation
  • Pharmaceutical regulatory services
  • Life sciences consulting
  • Regulatory affairs support

Where Trilogy Writing & Consulting is headquartered

Location

Headquarters

HQ city
Frankfurt
HQ country
Germany
HQ region
Europe

Markets served

Trilogy Writing & Consulting business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Trilogy Writing & Consulting product offering

Product offering

Core offering

Trilogy Writing & Consulting provides specialized regulatory and clinical documentation services for the life sciences sector. The firm supports pharmaceutical and biotechnology companies in producing documentation required for clinical development, regulatory submissions, and compliance with stringent regulatory frameworks. It operates as a regulatory medical writing consultancy with deep domain expertise in clinical and submission documentation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Regulatory Medical Writing Services
  • Clinical Trial Documentation Support
  • Regulatory Compliance Documentation for Biologics and Specialty Drugs

Companies that use Trilogy Writing & Consulting

Customer profile

Segments1 record

Ideal customer profiles1 record

Trilogy Writing & Consulting technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Trilogy Writing & Consulting partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves1 record

Expansion highlights4 records

Trilogy Writing & Consulting competitors and assessment

Company assessment

Broad incumbents

  • Labcorp Drug Development (Covance): Labcorp Drug Development, formerly Covance, provides clinical development and regulatory services including medical writing to pharma sponsors. Its integrated CRO model with embedded writing functions makes it a broadly comparable incumbent peer to Trilogy's specialized offering.
  • ICON plc: ICON is a leading global CRO with significant regulatory writing, biostatistics, and clinical services capabilities. It is a direct competitor for outsourced regulatory writing contracts with pharma and biotech sponsors and offers comparable FSP-style engagements at global scale.
  • Indegene Limited: Indegene is Trilogy's parent company and a global healthcare commercialization and clinical services firm. While Indegene operates across the broader pharma services value chain, its regulatory writing portfolio — of which Trilogy is the centerpiece — directly overlaps with Trilogy's specialty. It is the most relevant comparison for benchmarking Trilogy's service scope and scale within a strategic acquirer's platform.
  • IQVIA: IQVIA is a global CRO and life sciences services giant offering regulatory and medical writing within its broader clinical development portfolio. While its remit extends across the full clinical and commercial stack, its medical writing practice competes for the same embedded writing engagements Trilogy targets, making it a relevant broad incumbent peer.
  • Syneos Health: Syneos Health is a clinical and commercial services organization offering regulatory and medical writing within its broader biopharmaceutical solutions portfolio. It serves similar sponsor customers and competes for similar writing engagements.

Direct peers

  • Parexel International: Parexel is a top-tier CRO with dedicated regulatory writing and medical communications services serving global pharma and biotech sponsors. It competes directly with Trilogy for the same regulatory documentation work and across similar clinical submission use cases, and is one of the most direct comparables in the medical writing FSP space.
  • Freyr Solutions: Freyr is a global regulatory services and medical writing specialist serving pharma, biotech, and medical device companies. Its dedicated focus on regulatory documentation, submissions, and compliance aligns closely with Trilogy's core offering and customer base.
  • Cactus Communications: Cactus Communications, through its Cactus Life Sciences division, provides medical writing, publication support, and regulatory documentation services to global pharma and biotech sponsors. It is one of the closest direct peers to Trilogy in terms of pure-play medical writing and FSP offerings for clinical and regulatory documents.

Emerging players

  • ProPharma Group (now part of PACE): ProPharma Group provides regulatory affairs, compliance, and medical writing consulting services to pharma and biotech. Its overlap with Trilogy is more concentrated in regulatory and quality-focused projects, positioning it as a focused emerging player in adjacent regulatory services.

Regional players

  • TFS HealthScience / Ergomed: TFS HealthScience (acquired by Ergomed) is a European-headquartered CRO with a strong medical writing and clinical services practice serving global sponsors. Its Nordic and European base, combined with writing-focused FSP services, makes it a directly comparable European regional peer to Trilogy's Frankfurt-rooted operation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Trilogy Writing & Consulting social profiles

Digital presence

Trilogy Writing & Consulting financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Trilogy Writing & Consulting leadership team

Management profile

Number of profiles

Trilogy Writing & Consulting funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Trilogy Writing & Consulting M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trilogy Writing & Consulting

What does Trilogy Writing & Consulting do?

Trilogy Writing & Consulting provides specialized regulatory and clinical documentation services for the life sciences sector. The firm supports pharmaceutical and biotechnology companies in producing documentation required for clinical development, regulatory submissions, and compliance with stringent regulatory frameworks. It operates as a regulatory medical writing consultancy with deep domain expertise in clinical and submission documentation.

Is Trilogy Writing & Consulting a public or private company?

Trilogy Writing & Consulting is a private company. It is classified as corporate owned and is currently acquired.

When was Trilogy Writing & Consulting founded?

Trilogy Writing & Consulting was founded in 2002. It employs 101 to 250 people.

Where is Trilogy Writing & Consulting based?

Trilogy Writing & Consulting is headquartered in Frankfurt, Germany, in the Europe region.

Who are Trilogy Writing & Consulting's main competitors?

Broad incumbents on record are Labcorp Drug Development (Covance), ICON plc, Indegene Limited, IQVIA and Syneos Health. Direct peers are Parexel International, Freyr Solutions and Cactus Communications. ProPharma Group (now part of PACE) is listed as an emerging player. TFS HealthScience / Ergomed is listed as a regional player.

Does Trilogy Writing & Consulting have an API?

No public API is recorded for Trilogy Writing & Consulting.

What industry is Trilogy Writing & Consulting in?

Trilogy Writing & Consulting's product category is Regulatory Medical Writing Services. Its primary akta.pro industry code is HLAGALAG, Medical Writing & Publications (Clinical/Safety/HEOR), with a secondary code of HLAGAOAC, Medical Writing & Clinical Documentation FSP. Its NAICS code is 54169 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAI in Medical Writing Market Trends & Insights: Competitive Forecast to 2026The AI in medical writing market is projected to grow from $1.05 billion in 2025 to $1.99 billion by 2030, driven by increasing clinical trial volume, regulatory documentation complexity, and adoption of generative AI models. Indegene Limited acquired Trilogy Writing & Consulting GmbH in March 2024 to expand its regulatory writing capabilities, while TrialAssure launched its AI-powered document generation tool TrialAssure LINK AI 2 in June 2024. North America leads the market, though tariffs are increasing costs for cross-border cloud infrastructure services, prompting regional data center investments.EIN PresswireMedical Writing Market to Reach USD 10.67 Billion by 2032 | Size, Share, Trends, Forecast, Demand & Competitive AnalysisThe global medical writing market is expanding rapidly, driven by adoption of AI tools, natural language processing, and real-world evidence integration, focusing on clinical, regulatory, and scientific communication. Major regions include North America and Europe, with key contributions from companies like Trilogy Writing and Freyr; the market is expected to reach USD 10.67 billion by 2032.Business & FinancialAI In Medical Writing Market To Witness Astonishing Growth Trilogy Writing & Consulting, CertaraThe global AI in medical writing market is projected to grow at a CAGR of 11.5% from 2024 to 2030, according to HTF Market Intelligence. The report identifies key players including Trilogy Writing & Consulting, Certara, and Cactus Communications, and highlights drivers such as demand for evidence-based content and automation of routine tasks.GlobeNewswireIndegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancyIndegene acquired Trilogy Writing & Consulting GmbH, a medical writing consultancy, to augment its clinical and regulatory writing expertise. The medical writing market was $4.2 billion in 2023 and is forecast to grow to $8.4 billion by 2030. Indegene plans to combine Trilogy's expertise with its Generative AI capabilities to improve productivity and regulatory outcomes.GlobeNewswireIndegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancyIndegene acquired Trilogy Writing & Consulting, a medical writing consultancy, to augment its clinical and regulatory writing expertise. The medical writing market was $4.2 billion in 2023 and is forecast to grow to $8.4 billion by 2030. Indegene plans to combine Trilogy's expertise with its Generative AI capabilities to improve productivity and regulatory approval timelines.